Aquestive Therapeutics Inc at JMP Securities Life Sciences Conference Transcript
Good afternoon, everybody. Thank you again for joining us at the JMP Securities Life Science Conference. I'm Jason Butler, a member of the research team here at JMP. Excited to be joined next by Aquestive Therapeutics.
Aquestive is a company that has a pipeline of approved and development-stage candidates that are leveraging a core film technology, which we'll get into. An exciting year behind and ahead of us. Lead program AQST-109 for development of treatment of anaphylaxis. It's a sublingual oral form of epinephrine. And beyond that, there are, again, a broad pipeline, which we'll talk about.
Happy to be joined by Dan Barber, company CEO; and several members of the senior management team, which, Dan, I'll let you introduce. But Dan, thank you for being with us.
Thanks for having us, Jason. We appreciate it. We appreciate JMP hosting this event. And yes, I did bring a small army with me today, so I apologize for that.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |